Mikhail T Silk1, Thomas Wimmer2, Kyungmouk S Lee3, Govindarajan Srimathveeravalli3, Karren T Brown3, Peter T Kingham4, Yuman Fong4, Jeremy C Durack3, Constantinos T Sofocleous3, Stephen B Solomon3. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 444 East 68th Street, New York, NY 10065. Electronic address: Mikhail.Silk@gmail.com. 2. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 444 East 68th Street, New York, NY 10065; Department of Radiology, Medical University of Graz, Graz, Austria. 3. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 444 East 68th Street, New York, NY 10065. 4. Department of Surgery, Memorial Sloan-Kettering Cancer Center, 444 East 68th Street, New York, NY 10065.
Abstract
PURPOSE: To assess biliary complications after irreversible electroporation (IRE) ablation of hepatic tumors located < 1 cm from major bile ducts. MATERIALS AND METHODS: A retrospective review was conducted of all percutaneous IRE ablations of hepatic tumors within 1 cm of the common, left, or right hepatic ducts at a single institution from January 2011 to September 2012. Computed tomography imaging performed before and after treatment was examined for evidence of bile duct dilatation, stricture, or leakage. Serum bilirubin and alkaline phosphatase levels were analyzed for evidence of biliary injury. RESULTS: There were 22 hepatic metastases in 11 patients with at least one tumor within 1 cm of the common, left, or right hepatic duct that were treated with IRE ablations in 15 sessions. Median tumor size treated was 3.0 cm (mean, 2.8 cm ± 1.2, range, 1.0-4.7 cm). Laboratory values obtained after IRE were considered abnormal after four treatment sessions in three patients (bilirubin, 2.6-17.6 mg/dL; alkaline phosphatase, 130-1,035 U/L); these abnormal values were transient in two sessions. Two patients had prolonged elevation of values, and one required stent placement; both of these conditions appeared to be secondary to tumor progression rather than bile duct injury. CONCLUSIONS: This clinical experience suggests that IRE may be a treatment option for centrally located liver tumors with margins adjacent to major bile ducts where thermal ablation techniques are contraindicated. Further studies with extended follow-up periods are necessary to establish the safety profile of IRE in this setting.
PURPOSE: To assess biliary complications after irreversible electroporation (IRE) ablation of hepatic tumors located < 1 cm from major bile ducts. MATERIALS AND METHODS: A retrospective review was conducted of all percutaneous IRE ablations of hepatic tumors within 1 cm of the common, left, or right hepatic ducts at a single institution from January 2011 to September 2012. Computed tomography imaging performed before and after treatment was examined for evidence of bile duct dilatation, stricture, or leakage. Serum bilirubin and alkaline phosphatase levels were analyzed for evidence of biliary injury. RESULTS: There were 22 hepatic metastases in 11 patients with at least one tumor within 1 cm of the common, left, or right hepatic duct that were treated with IRE ablations in 15 sessions. Median tumor size treated was 3.0 cm (mean, 2.8 cm ± 1.2, range, 1.0-4.7 cm). Laboratory values obtained after IRE were considered abnormal after four treatment sessions in three patients (bilirubin, 2.6-17.6 mg/dL; alkaline phosphatase, 130-1,035 U/L); these abnormal values were transient in two sessions. Two patients had prolonged elevation of values, and one required stent placement; both of these conditions appeared to be secondary to tumor progression rather than bile duct injury. CONCLUSIONS: This clinical experience suggests that IRE may be a treatment option for centrally located liver tumors with margins adjacent to major bile ducts where thermal ablation techniques are contraindicated. Further studies with extended follow-up periods are necessary to establish the safety profile of IRE in this setting.
Authors: Michael J Ryan; Jonathon Willatt; Bill S Majdalany; Ania Z Kielar; Suzanne Chong; Julie A Ruma; Amit Pandya Journal: World J Hepatol Date: 2016-01-28
Authors: Russell C Langan; Debra A Goldman; Michael I D'Angelica; Ronald P DeMatteo; Peter J Allen; Vinod P Balachandran; William R Jarnagin; T Peter Kingham Journal: J Surg Oncol Date: 2017-05-11 Impact factor: 3.454
Authors: Eisuke Ueshima; Mark Schattner; Robin Mendelsohn; Hans Gerdes; Sebastien Monette; Haruyuki Takaki; Jeremy C Durack; Stephen B Solomon; Govindarajan Srimathveeravalli Journal: Gastrointest Endosc Date: 2017-05-10 Impact factor: 9.427
Authors: Govindarajan Srimathveeravalli; Mikhail Silk; Thomas Wimmer; Sebastien Monette; Simon Kimm; Majid Maybody; Stephen B Solomon; Jonathan Coleman; Jeremy C Durack Journal: J Vasc Interv Radiol Date: 2015-03-11 Impact factor: 3.464
Authors: Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742